Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C.
An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.
Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.
Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.
Response to: Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications, by Jerome Boursier et al.
External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.
Non-invasive diagnosis and follow-up of chronic infection with Hepatitis C Virus.
Non-invasive diagnosis and follow-up of portal hypertension.
Concordance of non-invasive serology-based scoring indices and transient elastography for liver fibrosis and cirrhosis in chronic hepatitis C.
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.
Prevalence of liver fibrosis and cirrhosis in 699 Moroccan patients with chronic hepatitis C.
